Cingulate (CING) Cash from Investing Activities (2021 - 2025)
Cingulate's (CING) quarterly Cash from Investing Activities came in at -$156213.0 in Q4 2025, up 21.29% YoY from -$128794.9 in Q4 2024, and up 21.29% on a QoQ basis from -$198462.0 in Q4 2024.
Cingulate (CING) Cash from Investing Activities (2021 - 2025) Analysis & Trends
Cingulate (CING) has 5 years of Cash from Investing Activities data on file, last reported at -$156213.0 in Q4 2025.
- Quarterly Cash from Investing Activities rose 21.29% year-over-year to -$156213.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$286505.0 (down 35.27% YoY) and the FY2025 annual result came in at -$162138.0, up 23.45% from the prior year.
- Cash from Investing Activities climbed to -$156213.0 in Q4 2025, from -$198462.0 in the prior quarter.
- In the past five years, Cash from Investing Activities ranged from a high of $140795.0 in Q3 2024 to a low of -$710007.0 in Q4 2021.
- A 5-year average of -$97468.6 and a median of -$51802.0 in 2021 frame the typical range for Cash from Investing Activities.
- Annual changes were most pronounced in 2022 — Cash from Investing Activities jumped 120.6% — and 2024, when it slumped 7262400.0%.
- Tracing CING's Cash from Investing Activities over 5 years: stood at -$710007.0 in 2021, then surged by 79.86% to -$143020.0 in 2022, then tumbled by 30.72% to -$186960.0 in 2023, then slipped by 6.15% to -$198462.0 in 2024, then climbed by 21.29% to -$156213.0 in 2025.
- The last three Cash from Investing Activities figures came in at -$156213.0 (Q4 2025), -$198462.0 (Q4 2024), and $140795.0 (Q3 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -45.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -92.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 329.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -49.35 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -363.46 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -3.17 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 24.51 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -229.72 Mn |
| 10 | Cingulate | 72.85 Mn | 72.85 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -156,213.00 |
| Dec 31, 2025 | -156,213.00 |
| Dec 31, 2024 | -198,462.00 |
| Dec 31, 2024 | -198,462.00 |
| Sep 30, 2024 | 140,795.00 |
| Sep 30, 2024 | 140,795.00 |
| Jun 30, 2024 | -72,625.00 |
| Jun 30, 2024 | -72,625.00 |
| Mar 31, 2024 | -81,508.00 |
| Mar 31, 2024 | -81,508.00 |
| Dec 31, 2023 | -186,960.00 |
| Dec 31, 2023 | -186,960.00 |
| Jun 30, 2023 | -1.00 |
| Jun 30, 2023 | -1.00 |
| Mar 31, 2023 | -37,135.00 |
| Mar 31, 2023 | -37,135.00 |
| Dec 31, 2022 | -143,020.00 |
| Dec 31, 2022 | -143,020.00 |
| Sep 30, 2022 | 3,250.00 |
| Sep 30, 2022 | 3,250.00 |